Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Philippe Durand

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
JPEN. Journal of Parenteral and Enteral Nutrition|March 6, 2018
Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 StudyEmmanuel Gyan, Bruno Raynard, Jean-Philippe Durand, et al.
Cancers|July 9, 2022
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with NivolumabJohanna Noel, Anne Jouinot, Jérôme Alexandre, et al.
Ebiomedicine|October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY studyPascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
JPEN. Journal of Parenteral and Enteral Nutrition|March 6, 2018
Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 StudyEmmanuel Gyan, Bruno Raynard, Jean-Philippe Durand, et al.
Cancers|July 9, 2022
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with NivolumabJohanna Noel, Anne Jouinot, Jérôme Alexandre, et al.
Ebiomedicine|October 23, 2021
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY studyPascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 25, 2019
Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patientsAnne Jouinot, Guillaume Ulmann, Clara Vazeille, et al.
Pageof 4